Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

BACKGROUND: Drugs modifying angiotensin II signalling could reduce Alzheimer's disease pathology, thus decreasing the rate of disease progression. We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Kehoe, Patrick Gavin, Turner, Nicholas, Howden, Beth, Jarutyte, Lina, Clegg, Shona Louise, Malone, Ian Brian, Barnes, Josephine, Nielsen, Casper, Sudre, Carole Hélène, Wilson, Aileen, Thai, Ngoc Jade, Blair, Peter Sinclair, Coulthard, Elizabeth, Lane, Janet Athene, Passmore, Peter, Taylor, Jodi, Mutsaerts, Henk-Jan, Thomas, David Lee, Fox, Nick Charles, Wilkinson, Ian, Ben-Shlomo, Yoav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528717/
https://www.ncbi.nlm.nih.gov/pubmed/34687634
http://dx.doi.org/10.1016/S1474-4422(21)00263-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528717/
https://www.ncbi.nlm.nih.gov/pubmed/34687634
http://dx.doi.org/10.1016/S1474-4422(21)00263-5

Ejemplares similares